Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (322)	3/23/2004 1:34:53 PM
From: Icebrg	Read Replies (1) \| Respond to of 590

Panitumumab (ABX-EGF) [From today's AMGN PR. The mAb has at least three different names by now]. Panitumumab (rHuMAb-EGFr) is the first fully human monoclonal antibody directed against the epidermal growth factor receptor (EGFr). It is being evaluated as monotherapy and in combination with other agents for the treatment of various solid tumor cancers in partnership with Abgenix, Inc. In 2004, Amgen initiated pivotal clinical studies in panitumumab as a third-line monotherapy in colorectal cancer patients with a convenient every-other-week dosing regimen.